Company

Last deal

$30.7M
Local Amount - CNY 200.M

Amount

Series A

Stage

27.07.2021

Date

1

all rounds

$30.7M

Total amount

General

About Company
Dinfectome develops molecular detection tech for pathogenic microorganisms, improving liquid biopsy and precision medicine in cancer.

Industry

Sector :

Subsector :

Also Known As

迪飞医学

founded date

01.01.2018

Last funding type

Series A

IPO status

Private

Description

Dinfectome researches and develops molecular detection technology. It provides biotechnology solutions to improve testing of various diseases. Dinfectome is based in Nanjing, China.